GTB-5550 for Cancer

This trial explores a new treatment called GTB-5550 for individuals with certain advanced or metastatic cancers. GTB-5550 targets cancer cells with a specific marker known as B7-H3. The trial seeks to determine the safety of the treatment and its potential effectiveness against these cancers. Individuals with advanced cancer unresponsive to other treatments and with a cancer type exhibiting high levels of B7-H3 may be suitable candidates for this trial. Participants will receive varying doses of GTB-5550 to identify the most effective and safe dose. As a Phase 1 trial, this research focuses on understanding how GTB-5550 works in people, offering participants the opportunity to be among the first to receive this innovative treatment.

The trial protocol does not specify if you need to stop taking your current medications. However, you cannot have had any anti-cancer treatment, including surgery, radiotherapy, chemotherapy, or other immunotherapy, within 14 days before starting the trial. It's best to discuss your specific medications with the trial team.

Research has shown that GTB-5550, the treatment under study, is in the early stages of human testing. This means limited information exists about its safety for humans. At this stage, treatments are primarily tested to assess safety and the body's response.

GTB-5550 is a TriSpecific Killer Engager (TriKE) designed to help the immune system identify and destroy cancer cells. Although GTB-5550 is being tested in humans for the first time, similar treatments have been well-tolerated previously. For instance, GTB-3550 was found to be safe and tolerable in earlier studies.

Since GTB-5550 is in a Phase 1 trial, researchers closely monitor for any side effects. They will make changes to improve safety if any issues arise.

Researchers are excited about GTB-5550 because it offers a new approach to treating advanced or metastatic cancer. Unlike traditional treatments such as chemotherapy and radiation, which can affect healthy cells, GTB-5550 targets cancer cells more selectively. This precision reduces the potential for side effects and improves the overall effectiveness of the treatment. Additionally, GTB-5550 is being tested in various dose levels, which helps researchers find the optimal dosage to maximize benefits while minimizing risks. This innovative approach holds promise for improving outcomes for patients with difficult-to-treat cancers.

Studies have shown that GTB-5550 targets a protein called B7-H3, found in many solid tumors. This protein often appears in advanced cancers, making it a promising treatment target. GTB-5550 guides the body’s natural killer (NK) cells to attack cancer cells. Early research in labs and animals has shown positive results, suggesting it might help reduce tumor growth. Although human studies provide limited information, the mechanism of GTB-5550 offers strong reason to believe it could be effective against cancers with the B7-H3 protein. Participants in this trial will receive varying doses of GTB-5550 to evaluate its safety and effectiveness.¹³⁶⁷⁸